Telix Pharmaceuticals | TLX - Selling And Administration Expenses

Stock Price
14.26
Daily Change
-0.46 -3.13%
Monthly
-3.39%
Yearly
-44.60%
Q2 Forecast
14.44

Telix Pharmaceuticals reported AUD93.48M in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Cochlear AUD 449.4M 214.45M Dec/2025
CSL USD 1.23B 498M Dec/2025
Integral Diagnostics AUD 169.98M 18.73M Jun/2024
Mayne Pharma AUD 54.8M 11.94M Jun/2024
Medical Developments International AUD 2.84M 4.19M Dec/2025
Mesoblast USD 28.54M 9.69M Dec/2025
Neuren Pharmaceuticals AUD 3.74M 2.5M Dec/2025
Pacific Edge NZD 19.17M 1.32M Dec/2025
Paradigm Biopharmaceuticals AUD 2.83M 1.22M Dec/2025
Polynovo AUD 17.04M 1.91M Dec/2025
PYC Therapeutics AUD 328.4K 1.8M Dec/2025
Ramsay Health Care AUD 5.29B 3.2M Dec/2024
ResMed USD 275.7M 16.51M Dec/2025
Sonic Healthcare AUD 2.52B 2.46B Dec/2024